Efficacy of topical blockade of interleukin-1 in experimental dry eye disease

American Journal of Ophthalmology

Volumn 154, Issue 1, 2012, Pages 63-71

  Okanobo, Andre ^a   Chauhan, Sunil K ^a   Dastjerdi, Mohammad H ^a   Kodati, Shilpa ^a   Dana, Reza ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CYCLOSPORIN A; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; MESSENGER RNA; METHYLPREDNISOLONE; PROMETHAZINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; DRY EYE; FEMALE; GENE EXPRESSION; LYMPHANGIOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIGENS, CD11B; CYCLOSPORINE; DISEASE MODELS, ANIMAL; DRY EYE SYNDROMES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; FLUOROPHOTOMETRY; GLUCOCORTICOIDS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; METHYLPREDNISOLONE; MICE; MICE, INBRED C57BL; OPHTHALMIC SOLUTIONS; REAL-TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 84862768738     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2012.01.034     Document Type: Article

References (47)

1. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5(2):75-92.
2. Miljanovic B, Dana R, Sullivan DA, Schaumberg DA. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol 2007;143(3):409-415.
3. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol 2004;137(2):337-342. (Pubitemid 38221009)
4. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology 1999;106(4):811-816. (Pubitemid 30194327)
5. Brown MM, Brown GC, Brown HC, Peet J, Roth Z. Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome. Arch Ophthalmol 2009;127(2):146-152.
6. Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 2000;11(6):478-483.
7. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000;107(4):631-639. (Pubitemid 30191329)
8. Gabay C, Porter B, Fantuzzi G, Arend WP. Mouse IL-1 receptor antagonist isoforms: complementary DNA cloning and protein expression of intracellular isoform and tissue distribution of secreted and intracellular IL-1 receptor antagonist in vivo. J Immunol 1997;159(12):5905-5913. (Pubitemid 127471525)
9. Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993;54:167-227. (Pubitemid 23289253)
10. Bresnihan B, Cunnane G. Interleukin-1 receptor antagonist. Rheum Dis Clin North Am 1998;24(3):615-628. (Pubitemid 28416812)
11. Moreland LW. The role of cytokines in rheumatoid arthritis: inhibition of cytokines in therapeutic trials. Drugs Today (Barc) 1999;35(4 -5):309-319.
12. Fisher CJJ, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994;271(23):1836-1843. (Pubitemid 24169697)
13. Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci 2001;42(10):2283-2292. (Pubitemid 32848857)
14. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87(6):2095-2147. (Pubitemid 26086851)
15. Stern ME, Pflugfelder SC. Inflammation in dry eye. Ocul Surf 2004;2(2):124-130. (Pubitemid 41263879)
16. Barabino S, Shen L, Chen L, Rashid S, Rolando M, Dana MR. The controlled-environment chamber: a new mouse model of dry eye. Invest Ophthalmol Vis Sci 2005;46(8):2766-2771. (Pubitemid 43086697)
17. Goyal S, Chauhan SK, El Annan J, Nallasamy N, Zhang Q, Dana R. Evidence of corneal lymphangiogenesis in dry eye disease: a potential link to adaptive immunity? Arch Ophthalmol 2010;128(7):819-824.
18. Goyal S, Chauhan SK, Dana R. Blockade of prolymphangiogenic vascular endothelial growth factor C in dry eye disease. Arch Ophthalmol 2012;130(1):84-89.
19. Barabino S, Rolando M, Chen L, Dana MR. Exposure to a dry environment induces strain-specific responses in mice. Exp Eye Res 2007;84(5):973-977. (Pubitemid 46613883)
20. Barabino S, Chen W, Dana MR. Tear film and ocular surface tests in animal models of dry eye: uses and limitations. Exp Eye Res 2004;79(5):613-621. (Pubitemid 39410364)
21. Maruyama K, Ii M, Cursiefen C, et al. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest 2005;115(9):2363-2372. (Pubitemid 41266198)
22. Bock F, Onderka J, Hos D, Horn F, Martus P, Cursiefen C. Improved semiautomatic method for morphometry of angiogenesis and lymphangiogenesis in corneal flatmounts. Exp Eye Res 2008;87(5):462-470.
23. Hamrah P, Zhang Q, Liu Y, Dana MR. Novel characterization of MHC class II-negative population of resident corneal Langerhans cell-type dendritic cells. Invest Ophthalmol Vis Sci 2002;43(3):639-646. (Pubitemid 34184478)
24. Rashid S, Jin Y, Ecoiffier T, Barabino S, Schaumberg DA, Dana MR. Topical omega-3 and omega-6 fatty acids for treatment of dry eye. Arch Ophthalmol 2008;126(2):219-225. (Pubitemid 351240851)
25. Cursiefen C, Chen L, Saint-Geniez M, et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A 2006;103(30):11405-11410. (Pubitemid 44156530)
26. Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006;443(7114):993-997. (Pubitemid 44646176)
27. Hommel M. On the dynamics of T-cell activation in lymph nodes. Immunol Cell Biol 2004;82(1):62-66. (Pubitemid 38388721)
28. Wilson SE, Mohan RR, Mohan RR, Ambrosio RJ, Hong J, Lee J. The corneal wound healing response: cytokine-mediated interaction of the epithelium, stroma, and inflammatory cells. Prog Retin Eye Res 2001;20(5):625-637. (Pubitemid 32695343)
29. Chen M, Hu DN, Pan Z, Lu CW, Xue CY, Aass I. Curcumin protects against hyperosmoticity-induced IL-1beta elevation in human corneal epithelial cell via MAPK pathways. Exp Eye Res 2010;90(3):437-443.
30. Wilson SE, Esposito A. Focus on molecules: interleukin-1: a master regulator of the corneal response to injury. Exp Eye Res 2009;89(2):124-125.
31. Kimura K, Teranishi S, Nishida T. Interleukin-1beta-induced disruption of barrier function in cultured human corneal epithelial cells. Invest Ophthalmol Vis Sci 2009;50(2):597-603.
32. Dinarello CA. A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur J Immunol 2011;41(5):1203-1217.
33. Hamrah P, Liu Y, Zhang Q, Dana MR. The corneal stroma is endowed with a significant number of resident dendritic cells. Invest Ophthalmol Vis Sci 2003;44(2):581-589. (Pubitemid 36159702)
34. Yamada J, Dana MR, Zhu SN, Alard P, Streilein JW. Interleukin 1 receptor antagonist suppresses allosensitization in corneal transplantation. Arch Ophthalmol 1998;116(10):1351-1357. (Pubitemid 28473841)
35. Yamagami S, Hamrah P, Miyamoto K, et al. CCR5 chemokine receptor mediates recruitment of MHC class II-positive Langerhans cells in the mouse corneal epithelium. Invest Ophthalmol Vis Sci 2005;46(4):1201-1207. (Pubitemid 41685854)
36. Stapleton WM, Chaurasia SS, Medeiros FW, Mohan RR, Sinha S, Wilson SE. Topical interleukin-1 receptor antagonist inhibits inflammatory cell infiltration into the cornea. Exp Eye Res 2008;86(5):753-757.
37. Jager MJ, Bradley D, Atherton S, Streilein JW. Presence of Langerhans cells in the central cornea linked to the development of ocular herpes in mice. Exp Eye Res 1992;54(6):835-841.
38. Niederkorn JY, Stern ME, Pflugfelder SC, et al. Desiccating stress induces T cell-mediated Sjogren's syndrome-like lacrimal keratoconjunctivitis. J Immunol 2006;176(7):3950-3957. (Pubitemid 44264372)
39. El Annan JCSK, Ecoiffier T, Zhang Q, Saban DR, Dana R. Characterization of effector T cells in dry eye disease. Invest Ophthalmol Vis Sci 2009;50(8):3802-3807.
40. Watari K, Nakao S, Fotovati A, et al. Role of macrophages in inflammatory lymphangiogenesis: enhanced production of vascular endothelial growth factor C and D through NF-KappaB activation. Biochem Biophys Res Commun 2008;377(3):826-831.
41. Xu H, Chen M, Reid DM, Forrester JV. LYVE-1-positive macrophages are present in normal murine eyes. Invest Ophthalmol Vis Sci 2007;48(5):2162-2171. (Pubitemid 351261290)
42. Kerjaschki D. The crucial role of macrophages in lymphangiogenesis. J Clin Invest 2005;115(9):2316 -2319.
43. Chauhan SK, Dana R. Role of Th17 cells in the immunopathogenesis of dry eye disease. Mucosal Immunol 2009;2(4):375-376.
44. De Paiva CS, Chotikavanich S, Pangelinan SB, et al. IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol 2009;2(3):243-253.
45. Chauhan SK, El Annan J, Ecoiffier T, et al. Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression. J Immunol 2009;182(3):1247-1252.
46. Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010;140(6):845-858.
47. Peck A, Mellins ED. Plasticity of T-cell phenotype and function: the T helper type 17 example. Immunology 2010;129(2):147-153.